FAP and hepatocellular carcinoma: Increased DPP-IV expression, possibly contributing to liver cancer progression by converting NPY to the Y5 receptor agonist NPY(3-36) [66], was further associated with tumor size, stage, and proliferation capacity in hepatocellular cancer.